Delivery Order SPE2DB20D2014-SPE2DB25FD05Q
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Otezla 30 mg tablets in a quantity of 60s at a firm fixed price of $2,802.78, with completion scheduled for September 9, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a $59,873.54 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Otezla 30 mg tablets (60-count units). This firm fixed price, competitively awarded contract is non-set-aside and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at the vendor's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $45,214.89 on September 11, 2025, for the supply of Otezla 30 mg tablets (60-count units). This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical products will be delivered to the company's distribution facility...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $27,320.78. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Otezla 30 mg tablets (60-count units) valued at $16,575.87 under a firm fixed-price arrangement. The contract is non-competitive with no set-aside designation and requires completion by September 11, 2025. This delivery order is issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999,999,999...
- The Defense Logistics Agency awarded a $7,891.76 delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count) on June 20, 2025, with completion scheduled for June 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $19,860.97 delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on June 26, 2025, with completion expected by June 27, 2025. This firm fixed-price contract represents a non-competitive set-aside and reflects AmerisourceBergen's critical role as a pharmaceutical distributor supporting federal medical procurement needs. The order is being performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract valued at $21,053.19. The contract, with an ultimate completion date of August 28, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued against...
- The Defense Logistics Agency awarded a $21,010.71 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Otezla 30 mg tablets (60-count). This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 17, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $18,324.62 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on September 3, 2025, with completion targeted for September 4, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FD05QDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Otezla 30 mg tablets in a 60-count quantity. This $12,417.30 firm fixed-price delivery order, which is not set-aside, is scheduled for completion by September 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through its comprehensive pharmaceutical supply capabilities. The company's DLA IDC vehicle enables it to deliver a broad range of medications and medical supplies to support military healthcare programs globally, including products for specialty care, chronic disease management, and preventive medicine. This delivery order for Otezla, an immunosuppressant medication, reflects the company's role in supplying brand-name pharmaceuticals to the Defense Health Agency and other federal healthcare systems through competitive procurement mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.4k | 9/19/25 |